{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"42","upperLimit":"51","value":"46"},{"groupId":"OG001","lowerLimit":"36","upperLimit":"51","value":"43"},{"groupId":"OG002","lowerLimit":"22","upperLimit":"50","value":"33"},{"groupId":"OG003","lowerLimit":"27","upperLimit":"60","value":"40"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"366"},{"groupId":"OG001","value":"156"},{"groupId":"OG002","value":"31"},{"groupId":"OG003","value":"29"}],"units":"Participants"}],"description":"Patients are considered a failure for this endpoint if they die or if they progress or relapse.","dispersionType":"95% Confidence Interval","groups":[{"description":"Tandem autologous transplant plus thalidomide/dexamethasone or observation for standard risk patients","id":"OG000","title":"Auto-Auto Standard Risk"},{"description":"Autologous transplant plus non-myeloablative allogeneic transplant for standard risk patients","id":"OG001","title":"Auto-Allo Standard Risk"},{"description":"Tandem autologous transplant plus thalidomide/dexamethasone or observation for high risk patients","id":"OG002","title":"Auto-Auto High Risk"},{"description":"Autologous transplant plus non-myeloablative allogeneic transplant for high risk patients","id":"OG003","title":"Auto-Allo High Risk"}],"paramType":"NUMBER","populationDescription":"Patients that completed second transplant","reportingStatus":"POSTED","timeFrame":"Year 3","title":"Progression-Free Survival (PFS)","type":"PRIMARY","unitOfMeasure":"percentage of patients"}